PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Targeted cancer therapy is increasingly important, differing from traditional chemoradiotherapy.
• Conventional imaging faces challenges in selecting patients and monitoring responses for targeted therapies.
• Molecular imaging is crucial for personalized cancer treatment strategies.

Purpose of the Study:

• To review the role of novel PET radiopharmaceuticals in guiding targeted cancer therapy.
• To highlight the application of PET/CT in patient selection and response assessment.
• To discuss the potential of molecular imaging in optimizing targeted treatment regimens.

Main Methods:

• Evaluation of various new PET radiopharmaceuticals for molecular imaging.
• Assessment of PET/CT agents targeting cell surface receptors, hormone receptors, receptor tyrosine kinases, and angiogenesis.
• Review of established and potential applications in clinical practice.

Main Results:

• PET/CT with new radiopharmaceuticals enables precise molecular imaging of therapeutic targets.
• These agents facilitate accurate patient selection for targeted therapies.
• PET/CT allows for effective monitoring of treatment response, guiding therapy adjustments.

Conclusions:

• PET/CT using novel radiopharmaceuticals is a valuable tool for guiding targeted cancer therapy.
• Molecular imaging improves patient stratification and treatment efficacy assessment.
• The integration of PET/CT enhances the precision and effectiveness of personalized cancer management.